CN111388655A - 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 - Google Patents

用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 Download PDF

Info

Publication number
CN111388655A
CN111388655A CN202010018792.0A CN202010018792A CN111388655A CN 111388655 A CN111388655 A CN 111388655A CN 202010018792 A CN202010018792 A CN 202010018792A CN 111388655 A CN111388655 A CN 111388655A
Authority
CN
China
Prior art keywords
inh
patients
organ
patient
amr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010018792.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·布鲁姆
M·E·尤克尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Viropharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111388655(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Holdings Ltd filed Critical Viropharma Holdings Ltd
Publication of CN111388655A publication Critical patent/CN111388655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202010018792.0A 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 Pending CN111388655A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US61/907,550 2013-11-22
US201462029086P 2014-07-25 2014-07-25
US62/029,086 2014-07-25
CN201480063697.5A CN105744949A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480063697.5A Division CN105744949A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Publications (1)

Publication Number Publication Date
CN111388655A true CN111388655A (zh) 2020-07-10

Family

ID=52016153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010018792.0A Pending CN111388655A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
CN201480063697.5A Pending CN105744949A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480063697.5A Pending CN105744949A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Country Status (24)

Country Link
US (3) US9895428B2 (https=)
EP (3) EP4162947A1 (https=)
JP (5) JP6431912B2 (https=)
KR (2) KR102312817B1 (https=)
CN (2) CN111388655A (https=)
AU (2) AU2014352846B2 (https=)
BR (1) BR112016011499A2 (https=)
CA (1) CA2930964A1 (https=)
CY (1) CY1121298T1 (https=)
DK (1) DK3071219T3 (https=)
ES (1) ES2708655T3 (https=)
HR (1) HRP20190184T1 (https=)
HU (1) HUE041809T2 (https=)
LT (1) LT3071219T (https=)
ME (1) ME03318B (https=)
MX (2) MX378834B (https=)
NZ (2) NZ719724A (https=)
PL (1) PL3071219T3 (https=)
PT (1) PT3071219T (https=)
RS (1) RS58343B1 (https=)
SG (1) SG10201804326SA (https=)
SI (1) SI3071219T1 (https=)
SM (1) SMT201900042T1 (https=)
WO (1) WO2015077543A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
CA3075686A1 (en) * 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US20220073605A1 (en) * 2018-12-20 2022-03-10 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
AU2020327043A1 (en) * 2019-08-08 2022-02-24 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
AU2021381360A1 (en) * 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518458A (zh) * 2001-03-01 2004-08-04 �ձ��̲ݲ�ҵ��ʽ���� 移植物排斥反应抑制剂
WO2013041677A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
RS53864B1 (sr) * 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
BR112015023207A8 (pt) * 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1518458A (zh) * 2001-03-01 2004-08-04 �ձ��̲ݲ�ҵ��ʽ���� 移植物排斥反应抑制剂
WO2013041677A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS等: "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation", CLINICALTRIALS.GOV, 15 February 2012 (2012-02-15), pages 1 - 6 *

Also Published As

Publication number Publication date
EP3071219B1 (en) 2018-11-14
CA2930964A1 (en) 2015-05-28
JP6620206B2 (ja) 2019-12-11
BR112016011499A2 (pt) 2020-10-27
AU2014352846A1 (en) 2016-06-02
SI3071219T1 (sl) 2019-03-29
JP2022179637A (ja) 2022-12-02
RS58343B1 (sr) 2019-03-29
MX2016006656A (es) 2016-09-06
JP2016537380A (ja) 2016-12-01
HUE041809T2 (hu) 2019-05-28
KR20160079821A (ko) 2016-07-06
JP2019023233A (ja) 2019-02-14
KR102312817B1 (ko) 2021-10-13
CN105744949A (zh) 2016-07-06
US20150147319A1 (en) 2015-05-28
JP2021063141A (ja) 2021-04-22
ME03318B (me) 2019-10-20
KR20210125118A (ko) 2021-10-15
MX378834B (es) 2025-03-11
PT3071219T (pt) 2019-02-06
HRP20190184T1 (hr) 2019-03-22
KR102384814B1 (ko) 2022-04-08
MX2021000332A (es) 2021-04-13
EP4162947A1 (en) 2023-04-12
AU2014352846B2 (en) 2019-10-03
LT3071219T (lt) 2019-01-10
WO2015077543A1 (en) 2015-05-28
JP2019001831A (ja) 2019-01-10
SG10201804326SA (en) 2018-06-28
NZ719724A (en) 2022-08-26
US20180104319A1 (en) 2018-04-19
DK3071219T3 (en) 2019-02-25
EP3494988A1 (en) 2019-06-12
CY1121298T1 (el) 2020-05-29
ES2708655T3 (es) 2019-04-10
JP6431912B2 (ja) 2018-11-28
EP3494988B1 (en) 2022-08-03
NZ759187A (en) 2022-08-26
PL3071219T3 (pl) 2019-04-30
US20200360495A1 (en) 2020-11-19
AU2020200015B2 (en) 2022-03-10
AU2020200015A1 (en) 2020-01-30
SMT201900042T1 (it) 2019-02-28
EP3071219A1 (en) 2016-09-28
US9895428B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
AU2020200015B2 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
JP2013213044A (ja) 溶血性疾患の処置方法
WO2022161484A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
HK40091830A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK40008415A (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK40008415B (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241B (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Charlotte Pharmaceutical Co., Ltd

Address before: Massachusetts, USA

Applicant before: VIROPHARMA HOLDINGS Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20210713

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: Charlotte Pharmaceutical Co., Ltd

TA01 Transfer of patent application right